SynthesisHead and neck pathology2024
Clinicopathological, Prognostic and Molecular Profile of Salivary Gland Intraductal Carcinoma: A Systematic Review.
Synthesis in Head and neck pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Invasive carcinoma ex intraductal carcinoma of the salivary gland showing extensive infiltrative growth despite deceptively low-grade cribriform morphology.Virchows Archiv : an international journal of pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThis study aimed to conduct a systematic review summarizing the clinicopathological, prognostic, and molecular features of salivary gland intraductal carcinoma (SGIC).
methodsThis study followed the PRISMA 2020 guidelines and was registered in the PROSPERO database. It included case reports, case series studies, and cohort studies of SGIC indexed in the PubMed, Web of Science, Scopus, and Embase databases published between 1983 and 2024. Collected variables underwent descriptive analysis, association analysis using Fisher's tests, and Kaplan-Meier analysis. The quality assessment of the included studies was conducted using the Joanna Briggs Institute tools.
resultsThis systematic review yielded 59 studies, comprising 186 SGIC cases. Most of cases involved the parotid gland of male patients around 60 years old. Lesions predominantly exhibited noninvasive growth, an intercalated duct phenotype, and minimal pleomorphism. Most of the patients did not develop recurrent or metastatic disease, indicating a good prognosis. However, male sex, invasive lesions, adjuvant treatments, high-grade lesions, as well as lymph node or distant metastasis negatively affected the survival rates. Overall SGIC cases showed S100, mammaglobin, SOX10, AR, CK7, p63, calponin, CK14, SMA, and p40 positivity and a low Ki67 index. Common molecular alterations included NCOA4-RET, TRIM33-RET, and TRIM27-RET fusions, and HRAS, PIK3CA, and BRAF V600E mutations.
conclusionSGIC is a histopathologically and molecularly heterogeneous lesion with an overall excellent prognosis. The presence of invasive lesions, as well as lymph node or distant metastasis, has emerged as one of the most critical prognostic factors in SGIC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.